Decision to not make a drug for childhood cancer on the NHS is 'devastating', say charities
Health watchdog Nice, which advises NHS England, stressed it would like to recommend dinutuximab beta for patients with neuroblastoma – but argued it is too expensive.
Decision to not make a drug for childhood cancer on the NHS is 'devastating', say charities
